Table.
Demographic and clinical characteristics of patients with COVID-19 with and without diarrhoea
| With diarrhoea (n=49) | Without diarrhoea (n=181) | p value | ||
|---|---|---|---|---|
| Age, years | 55 (40–65) | 46 (36–57) | 0·017 | |
| Sex | .. | .. | 0·87 | |
| Male | 27 (55%) | 102 (56%) | .. | |
| Female | 22 (45%) | 79 (44%) | .. | |
| Any comorbidity | 19 (39%) | 39 (22%) | 0·017 | |
| Date of admission to hospital | .. | .. | 0·022 | |
| Jan 19–Feb 11, 2020 | 40 (82%) | 169 (93%) | .. | |
| Feb 12–March 6, 2020 | 9 (18%) | 12 (7%) | .. | |
| Severe COVID-19 disease | 26 (53%) | 35 (19%) | <0·0001 | |
| Oxygen supplementation | 44 (90%) | 143 (79%) | 0·10 | |
| Ventilatory support | 6 (12%) | 3 (2%) | 0·0036 | |
| Intensive care | 15 (31%) | 20 (11%) | 0·0015 | |
| Died | 4 (8%) | 2 (1%) | 0·020 | |
| White blood cell count, ×109 cells per L | 5·6 (2·0) | 5·6 (3·0) | 1·0 | |
| Lymphocyte count, ×109 cells per L | 1·0 (0·6) | 1·1 (0·5) | 0·28 | |
| Neutrophil count, ×109 cells per L | 3·4 (1·8) | 3·9 (2·9) | 0·34 | |
| Alanine aminotransferase, U/L | 37·9 (27·4) | 34·0 (24·4) | 0·36 | |
| Aspartate aminotransferase, U/L | 39·3 (27·0) | 34·7 (17·9) | 0·19 | |
| Total bilirubin, μmol/L | 12·5 (7·3) | 11·5 (5·9) | 0·36 | |
| Activated partial thromboplastin time, s | 30·5 (9·5) | 31·0 (7·8) | 0·74 | |
| D-dimer, mg/L | 1·0 (1·8) | 1·6 (5·4) | 0·48 | |
| Procalcitonin, ng/mL | 0·29 (0·69) | 0·19 (0·36) | 0·25 | |
| Erythrocyte sedimentation rate, mm/h | 40·7 (30·0) | 23·8 (18·7) | 0·0002 | |
| C-reactive protein, mg/L | 40·5 (52·0) | 30·0 (38·3) | 0·16 | |
| Antibiotics | 36 (73%) | 138 (76%) | 0·71 | |
| Antiviral treatment | 49 (100%) | 180 (99%) | 1·0 | |
Data are median (IQR), n (%), or mean (SD). p values comparing patients with and without diarrhoea were calculated by use of Fisher's exact test, Mann–Whitney U test, or Student's t test. COVID-19=coronavirus disease 2019.